Answers are grounded in this paper and cite their sources.
ObjectiveDescribe global NMO SPOTLIGHT Registry (NCT05966467) patients with AQP4-Ab+ NMOSD treated with Alexion complement component 5 inhibitor therapies (ALXN-C5ITs) in real-world clinical practice. BackgroundALXN-C5ITs eculizumab and ravulizumab are approved in multiple countries for adults with AQP4-Ab+ NMOSD. The Registry collects ALXN-C5IT real-world safety and clinical effectiveness data in patients aged ≥18y. Design/MethodsAdults with AQP4-Ab+ NMOSD receiving ALXN-C5ITs were enrolled in the Registry starting August 2023. Data on demographics, relapses, infections, and vaccinations were collected. NMOSD relapse was defined as new onset/worsening neurologic symptoms for >24h requiring acute standard-of-care treatment preceded by ≥30d of clinical stability. Data were summarized for all patients, including patients who switched from rituximab (RTX). ResultsAs of 14Oct2024, 56 adults were enrolled in the Registry (median age at diagnosis, 46.5y). Median (IQR) duration of eculizumab (n=52) and ravulizumab (n=12) exposure was 42.5 (22.2-54.3) mo and 5.3 (4.0-14.1) mo, respectively. In 1y prior to ALXN-C5IT, 21 (37.5%) patients had 28 relapses (annualized relapse rate [ARR]: 0.50 [95% CI: 0.33-0.72]); 4/21 (19.0%) patients had >1 relapse. While on ALXN-C5IT, 3 (5.4%) patients had relapses (ARR: 0.02 [95% CI: 0.00-0.05]); no patients had >1 relapse. Among patients who switched from RTX to ALXN-C5IT (n=15; median time from last RTX discontinuation date to ALXN-C5IT initiation=141.5d, meningococcal vaccination=112d), 6 (40.0%) had 7 relapses in the 1y prior to ALXN-C5IT initiation (ARR: 0.47 [95% CI: 0.19-0.96]); none experienced a relapse while on ALXN-C5IT. In the 1y prior to ALXN-C5IT through Registry enrollment, 52 (92.9%) patients received ≥1 meningococcal vaccination. No receipt of a meningococcal or other vaccination in the 4w prior to relapse was reported; no meningococcal infections were reported. ConclusionsConsistent with previous clinical trial and real-world data, these results demonstrate the strong clinical benefit of eculizumab and ravulizumab in relapse prevention. No new safety signals were detected; no meningococcal infections were reported.
No takes yet. Share an insight, caveat, or question.
Sotirchos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: